1.40
-0.02(-1.41%)
Currency In USD
Address
Building 300
Cambridge, MA 02139
United States of America
Phone
617 914 8420
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Mr. Erik John Ostrowski M.B.A. | President, Interim Chief Executive Officer, Chief Financial Officer & Treasurer | 1.25M | 1972 |
| Mr. Steven N. Avruch J.D. | Chief Legal Officer & Secretary | 506,679 | 1962 |
| Dr. Azadeh Golipour Ph.D. | Chief Technology Officer | 1.01M | 1980 |
| Dr. Essra Ridha FFPM, M.D. | Chief Medical Officer | 1.12M | 1983 |
| Mr. Jeffrey Medin Ph.D. | Scientific Founder | 0 | N/A |
| Mr. Scott Gottesman | Vice President of Human Resource | 0 | N/A |
| Ms. Kirsten Dupuis | Chief of Staff | 0 | N/A |
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.